
## Augusto Villanueva

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8897328/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hepatocellular Carcinoma. New England Journal of Medicine, 2019, 380, 1450-1462.	27.0	2,966
2	Hepatocellular carcinoma. Nature Reviews Disease Primers, 2021, 7, 6.	30.5	2,757
3	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nature Genetics, 2015, 47, 505-511.	21.4	1,372
4	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics, 2008, 7, 3129-3140.	4.1	1,237
5	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. New England Journal of Medicine, 2008, 359, 1995-2004.	27.0	1,148
6	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology, 2015, 149, 1226-1239.e4.	1.3	980
7	Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma. Cancer Research, 2009, 69, 7385-7392.	0.9	978
8	Liver Cancer Cell of Origin, Molecular Class, and Effects onÂPatient Prognosis. Gastroenterology, 2017, 152, 745-761.	1.3	838
9	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology, 2017, 153, 812-826.	1.3	650
10	Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. Gastroenterology, 2008, 135, 1972-1983.e11.	1.3	644
11	Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma. Cancer Research, 2008, 68, 6779-6788.	0.9	589
12	Tumour evolution in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 139-152.	17.8	501
13	β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1124-1141.	9.4	498
14	Genomics and Signaling Pathways in Hepatocellular Carcinoma. Seminars in Liver Disease, 2007, 27, 055-076.	3.6	491
15	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nature Reviews Clinical Oncology, 2015, 12, 408-424.	27.6	456
16	Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes. Gastroenterology, 2013, 144, 829-840.	1.3	438
17	Targeted Therapies for Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 1410-1426.	1.3	408
18	Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 1501-1512.e2.	1.3	389

#	Article	IF	CITATIONS
19	A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis. Gastroenterology, 2006, 131, 1758-1767.	1.3	379
20	DNA methylationâ€based prognosis and epidrivers in hepatocellular carcinoma. Hepatology, 2015, 61, 1945-1956.	7.3	367
21	Systematic review: evidenceâ€based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials. Alimentary Pharmacology and Therapeutics, 2006, 23, 1535-1547.	3.7	341
22	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. Gastroenterology, 2013, 145, 176-187.	1.3	302
23	Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. Journal of Clinical Investigation, 2009, 119, 465-477.	8.2	298
24	Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 34-42.	17.8	277
25	Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements. Seminars in Liver Disease, 2010, 30, 035-051.	3.6	267
26	Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice. Gastroenterology, 2012, 143, 1660-1669.e7.	1.3	262
27	UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma. Cancer Cell, 2014, 25, 196-209.	16.8	261
28	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. Clinical Cancer Research, 2012, 18, 4997-5007.	7.0	251
29	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology, 2021, 73, 158-191.	7.3	235
30	Intratumoral heterogeneity and clonal evolution in liver cancer. Nature Communications, 2020, 11, 291.	12.8	230
31	Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy. Annual Review of Medicine, 2010, 61, 317-328.	12.2	229
32	Genetic profiling of hepatocellular carcinoma using next-generation sequencing. Journal of Hepatology, 2016, 65, 1031-1042.	3.7	219
33	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. Journal of Hepatology, 2010, 52, 550-559.	3.7	211
34	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. Journal of Hepatology, 2009, 51, 725-733.	3.7	206
35	MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. Gastroenterology, 2011, 140, 1618-1628.e16.	1.3	205
36	Experimental models of hepatocellular carcinoma. Journal of Hepatology, 2008, 48, 858-879.	3.7	203

#	Article	IF	CITATIONS
37	Prognostic Gene Expression Signature for Patients With Hepatitis C–Related Early-Stage Cirrhosis. Gastroenterology, 2013, 144, 1024-1030.	1.3	195
38	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut, 2019, 68, 1065-1075.	12.1	195
39	A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nature Biotechnology, 2009, 27, 264-274.	17.5	194
40	Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. Journal of Hepatology, 2012, 56, 1343-1350.	3.7	181
41	Cancer gene discovery in hepatocellular carcinoma. Journal of Hepatology, 2010, 52, 921-929.	3.7	173
42	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell, 2016, 30, 879-890.	16.8	172
43	Emerging Signaling Pathways in Hepatocellular Carcinoma. Liver Cancer, 2012, 1, 83-93.	7.7	169
44	Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. Journal of Hepatology, 2020, 73, 315-327.	3.7	164
45	Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut, 2017, 66, 530-540.	12.1	161
46	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. Journal of Hepatology, 2019, 70, 1262-1277.	3.7	150
47	Gene-expression signature of vascular invasion in hepatocellular carcinoma. Journal of Hepatology, 2011, 55, 1325-1331.	3.7	133
48	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nature Cancer, 2022, 3, 386-401.	13.2	126
49	Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020). Gastroenterology, 2021, 161, 879-898.	1.3	123
50	Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. Journal of Hepatology, 2017, 67, 1222-1231.	3.7	121
51	Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. Journal of Hepatology, 2017, 66, 952-961.	3.7	120
52	Pathogenesis of hepatocellular carcinoma and molecular therapies. Current Opinion in Gastroenterology, 2009, 25, 186-194.	2.3	118
53	New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers. Clinical Cancer Research, 2010, 16, 4688-4694.	7.0	114
54	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. Gastroenterology, 2015, 148, 806-818.e10.	1.3	109

#	Article	IF	CITATIONS
55	Mutational landscape of HCC—the end of the beginning. Nature Reviews Clinical Oncology, 2014, 11, 73-74.	27.6	108
56	A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut, 2016, 65, 1754-1764.	12.1	108
57	Biomarkers for Hepatobiliary Cancers. Hepatology, 2021, 73, 115-127.	7.3	104
58	IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Gastroenterology, 2016, 151, 1192-1205.	1.3	103
59	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Cancer Research, 2019, 79, 4326-4330.	0.9	99
60	Ras Promotes Growth by Alternative Splicing-Mediated Inactivation of the KLF6 Tumor Suppressor in Hepatocellular Carcinoma. Gastroenterology, 2008, 134, 1521-1531.	1.3	96
61	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology, 2021, 160, 2572-2584.	1.3	91
62	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut, 2023, 72, 129-140.	12.1	90
63	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene, 2018, 37, 3740-3752.	5.9	89
64	Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib. Clinical Cancer Research, 2012, 18, 1824-1826.	7.0	86
65	Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut, 2020, 69, 2025-2034.	12.1	77
66	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. Oncogene, 2021, 40, 140-151.	5.9	77
67	DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival. Clinical Cancer Research, 2015, 21, 925-933.	7.0	74
68	VEGF Signaling in Cancer Treatment. Current Pharmaceutical Design, 2014, 20, 2834-2842.	1.9	74
69	Intratumor Molecular and Phenotypic Diversity in Hepatocellular Carcinoma. Clinical Cancer Research, 2015, 21, 1786-1788.	7.0	73
70	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut, 2015, 64, 1296-1302.	12.1	70
71	Mitohormesis Primes Tumor Invasion and Metastasis. Cell Reports, 2019, 27, 2292-2303.e6.	6.4	69
72	Gene Signatures in the Management of Hepatocellular Carcinoma. Seminars in Oncology, 2012, 39, 473-485.	2.2	68

#	Article	IF	CITATIONS
73	Effect of HCV clearance with direct-acting antiviral agents on HCC. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 561-562.	17.8	67
74	High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. Scientific Reports, 2018, 8, 11570.	3.3	64
75	Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. British Journal of Cancer, 2019, 121, 340-343.	6.4	62
76	Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Current Opinion in Oncology, 2008, 20, 444-453.	2.4	60
77	Signaling pathways in hepatocellular carcinoma. Advances in Cancer Research, 2021, 149, 63-101.	5.0	56
78	Depicting the role of TP53 in hepatocellular carcinoma progression. Journal of Hepatology, 2011, 55, 724-725.	3.7	54
79	Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with <i>EGFR</i> . Hepatology, 2013, 57, 120-130.	7.3	52
80	Molecular Pathogenesis of Hepatocellular Carcinoma. Alcoholism: Clinical and Experimental Research, 2011, 35, 821-825.	2.4	47
81	The future of patient-derived tumor xenografts in cancer treatment. Pharmacogenomics, 2015, 16, 1671-1683.	1.3	43
82	The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. JHEP Reports, 2019, 1, 120-130.	4.9	43
83	DNA Methylation Profiling of Human Hepatocarcinogenesis. Hepatology, 2021, 74, 183-199.	7.3	42
84	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut, 2023, 72, 736-748.	12.1	42
85	Liquid biopsy in liver cancer. Discovery Medicine, 2015, 19, 263-73.	0.5	40
86	Signaling Pathways in Hepatocellular Carcinoma. Oncology, 2011, 81, 18-23.	1.9	39
87	Carcinogen-induced hepatic tumors in KLF6+/â^' mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology, 2011, 54, 522-531.	7.3	39
88	Why men are at higher risk for hepatocellular carcinoma?. Journal of Hepatology, 2012, 57, 453-454.	3.7	38
89	Molecular profiling to predict hepatocellular carcinoma outcome. Expert Review of Gastroenterology and Hepatology, 2009, 3, 101-103.	3.0	37
90	Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials. Journal of Hepatology, 2008, 49, 1-5.	3.7	35

#	Article	IF	CITATIONS
91	Management of small hepatocellular carcinoma in cirrhosis: Focus on portal hypertension. World Journal of Gastroenterology, 2013, 19, 1193.	3.3	34
92	Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis. JHEP Reports, 2021, 3, 100237.	4.9	32
93	Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology, 2012, 56, 1361-1370.	7.3	31
94	Inherited hepatocellular carcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 725-734.	2.4	28
95	Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans. Hepatology, 2019, 70, 2107-2122.	7.3	26
96	The transition from inflammation to cancer in the liver. Clinical Liver Disease, 2016, 8, 89-93.	2.1	25
97	Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing. BMC Medicine, 2020, 18, 200.	5.5	25
98	Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transplantation, 2020, 26, 823-831.	2.4	25
99	The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. Cancers, 2021, 13, 659.	3.7	25
100	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. Gut, 2022, 71, 2069-2080.	12.1	24
101	Safety of Percutaneous Ethanol Injection as Neoadjuvant Therapy for Hepatocellular Carcinoma in Waiting List Liver Transplant Candidates. Transplantation Proceedings, 2005, 37, 3871-3873.	0.6	21
102	Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma. Clinical Liver Disease, 2019, 14, 62-65.	2.1	21
103	Accuracy of plasma levels of polymorphonuclear elastase as early prognostic marker of acute pancreatitis in routine clinical conditions. European Journal of Gastroenterology and Hepatology, 2006, 18, 79-83.	1.6	20
104	Rethinking future development of molecular therapies in hepatocellular carcinoma: A bottom-up approach. Journal of Hepatology, 2013, 59, 392-395.	3.7	20
105	Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver diseaseâ€hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective. Clinical Liver Disease, 2016, 8, 100-104.	2.1	20
106	Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2. Breast Cancer Research, 2019, 21, 56.	5.0	19
107	Lymphotoxins: New Targets for Hepatocellular Carcinoma. Cancer Cell, 2009, 16, 272-273.	16.8	17
108	Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: A critical appraisal. Liver Transplantation, 2006, 12, 1747-1754.	2.4	16

#	Article	IF	CITATIONS
109	Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. Hepatology, 2012, 56, 2416-2419.	7.3	16
110	Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. Molecular Cancer Therapeutics, 2019, 18, 1506-1519.	4.1	16
111	Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. PLoS Genetics, 2021, 17, e1009589.	3.5	15
112	miRNA Delivery: Emerging Therapy for Hepatocellular Carcinoma. Gastroenterology, 2010, 138, 1202-1204.	1.3	13
113	Divergent evolutionary trajectories in transplanted tumor models. Nature Genetics, 2017, 49, 1565-1566.	21.4	13
114	Digital-resolution and highly sensitive detection of multiple exosomal small RNAs by DNA toehold probe-based photonic resonator absorption microscopy. Talanta, 2022, 241, 123256.	5.5	12
115	Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma. Oncoscience, 2018, 5, 209-211.	2.2	11
116	Update in the Therapeutic Management of Irritable Bowel Syndrome. Digestive Diseases, 2001, 19, 244-250.	1.9	9
117	microRNAs: New ways to block tumor angiogenesis?. Journal of Hepatology, 2012, 57, 490-491.	3.7	9
118	Liver capsule: Molecularâ€based signatures in hepatocellular carcinoma. Hepatology, 2016, 63, 2018-2018.	7.3	9
119	A phenotypical map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites. Histopathology, 2019, 74, 718-730.	2.9	9
120	Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B. JHEP Reports, 2021, 3, 100364.	4.9	9
121	Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clinical Cancer Research, 2022, 28, 2297-2305.	7.0	8
122	Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Cloneâ€Đependent Release of Circulating Tumor DNA. Hepatology Communications, 2021, 5, 1095-1105.	4.3	7
123	Molecular epidemiology in HCV-related hepatocellular carcinoma: First steps. Journal of Hepatology, 2012, 57, 213-214.	3.7	6
124	Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma. Seminars in Liver Disease, 2022, 42, 188-201.	3.6	6
125	Hepatocellular Carcinoma Enters the Sequencing Era. Gastroenterology, 2011, 141, 1943-1945.	1.3	5
126	Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015. Journal of Hepatology, 2015, 63, 753-762.	3.7	5

#	Article	IF	CITATIONS
127	Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors. Scientific Reports, 2020, 10, 5062.	3.3	5
128	Current management of liver cancer. European Journal of Cancer, Supplement, 2007, 5, 444-446.	2.2	4
129	Circulating tumor cells and cholangiocarcinoma. Hepatology, 2016, 63, 23-25.	7.3	4
130	Progress towards molecular patient stratification of hepatocellular carcinoma: Lost in translation?. Journal of Hepatology, 2017, 67, 893-895.	3.7	4
131	The usual SASPects of liver cancer. Aging, 2015, 7, 348-349.	3.1	4
132	Cell population genetics and deep sequencing: A novel approach for drivers discovery in hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 1198-1200.	3.7	3
133	Clinical Trial Watch: Reports from the Liver Meeting®, AASLD, San Francisco, November 2015. Journal of Hepatology, 2016, 64, 1428-1445.	3.7	3
134	Diagnostic and Prognostic Performance of Liquid Biopsy in Hepatocellular Carcinoma. Current Clinical Pathology, 2017, , 125-135.	0.0	3
135	Molecular profiling of liver cancer heterogeneity. Discovery Medicine, 2017, 24, 117-125.	0.5	3
136	Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Molecular Oncology, 2022, 16, 665-682.	4.6	3
137	Nontumor Prognostic Factors in Hepatocellular Carcinoma. , 2016, , 139-147.		2
138	The Impact of Translational Research in Hepatology. Clinical Liver Disease, 2019, 13, 29-33.	2.1	2
139	Genomic tracing of the elusive liver cancer ancestor. Journal of Hepatology, 2010, 53, 578-579.	3.7	1
140	Genetically engineered mouse models: future tools to predict clinical trial results in oncology?. Future Oncology, 2013, 9, 767-770.	2.4	1
141	Transplantation for hepatocellular carcinoma-worth waiting for?. Liver Transplantation, 2014, 20, 871-873.	2.4	1
142	Novel non-protein biomarkers for early detection of hepatocellular carcinoma. Engineering, 2021, 7, 1369-1369.	6.7	1
143	Selected summary for the 2015 Asia–Pacific Primary Liver Cancer Expert Meeting (APPLE). Hepatic Oncology, 2016, 3, 5-8.	4.2	0
144	Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 1-24.	0.1	0